Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease
The present review describes COVID-19 severity in diabetes and diabetic kidney disease. We discuss the crucial effect of COVID-19-associated cytokine storm and linked injuries and associated severe mesenchymal activation in tubular epithelial cells, endothelial cells, and macrophages that influence...
Main Authors: | Swayam Prakash Srivastava, Rohit Srivastava, Subhash Chand, Julie E. Goodwin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/8/751 |
Similar Items
-
Editorial: Combating Diabetes and Diabetic Kidney Disease
by: Swayam Prakash Srivastava, et al.
Published: (2021-07-01) -
Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review
by: Rodrigo Daza-Arnedo, et al.
Published: (2021-11-01) -
The role of dipeptidyl peptidase - 4 inhibitors in diabetic kidney disease
by: Usha ePanchapakesan, et al.
Published: (2015-08-01) -
Dipeptidyl-peptidase-4 inhibitors in type 2 diabetes and COVID-19: From a potential repurposed agent to a useful treatment option
by: Awadhesh Kumar Singh, et al.
Published: (2020-01-01) -
Efficacy and Safety of the Utilization of Dipeptidyl Peptidase IV Inhibitors in Diabetic Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials
by: Mahzari MM, et al.
Published: (2024-03-01)